ELECTRONIC LETTER

Mapping of a de novo unequal crossover causing a deletion of the steroid 21-hydroxylase (*CYP21A2*) gene and a non-functional hybrid tenascin-X (*TNXB*) gene

P F J Koppens, H J M Smeets, I J de Wijs, H J Degenhart

J Med Genet 2003;40:e53(<http://www.jmedgenet.com/cgi/content/full/40/5/e53>)

In the human genome, the major histocompatibility complex class III region on chromosome 6p21.3 stands out as an area of remarkably high gene density.^{1,2} Within this region, a section of particular complexity centres around the *C4* genes, which encode the fourth component of complement.³⁻⁷ Centromeric to *C4* lies the *CYP21A2* gene, which encodes steroid 21-hydroxylase, a key enzyme in the biosynthesis of cortisol and aldosterone.^{4,8,9} The *TNXB* gene, which encodes the extracellular matrix protein tenascin-X, lies centromeric to *CYP21A2* and is transcribed from the opposite strand.¹⁰⁻¹² Telomeric to *C4* lies the *RPI* gene, encoding a putative serine/threonine kinase.¹³⁻¹⁵ A typical chromosome 6 carries a duplication of an area of approximately 30 kb encompassing the entire *C4* and *CYP21* genes^{4,8} plus small truncated sections of *RP* and *TNX*.¹⁰⁻¹⁴ This tandem repeat has been named the RCCX module after its four constituent genes.^{7,14,16,17} In most white populations, about 70% of all haplotypes have a bimodular arrangement similar to the one shown in fig 1. The complex genetics of this region, and the activities and clinical significance of the proteins encoded here, have been the subject of several recent reviews.^{7,18-21}

Each chromosome 6 has at least one RCCX module, most have two as described above, some have three, and in rare cases as many as four contiguous RCCX modules have been found on a single chromosome. As bimodularity is the standard, publications often refer to haplotypes with one module as deletions, and to haplotypes with three modules as duplications, especially when focusing on the *C4* or *CYP21* genes. The overall layout of the RCCX region can be determined by short range and long range restriction mapping. Many studies have used *TaqI* and *BglII* restriction analysis of genomic DNA and comparison of the relative intensities of the bands obtained by hybridisation to *C4*, *CYP21A2*, and *TNXB* probes^{4,8,22-24} to establish haplotypes in families of patients with congenital adrenal hyperplasia and in controls. This approach is usually sufficient, but in complicated cases, rare cutters such as *SacII* or *BssHII* are needed to determine the size of the entire region and, hence, the number of RCCX modules.^{25,26}

The tandem repeat structure of the RCCX region promotes the chance of misalignment during meiosis. If a crossover then occurs, it effectively removes one of the modules. Between standard bimodular chromosomes, this process joins a part of the telomeric module to its homologous counterpart in the centromeric module (see fig 5 in the discussion for a typical example). The site of such a crossover determines whether or not the remaining monomodular chromosome carries a genetic disorder. An unequal crossover between *C4A* and *C4B* is relatively harmless, because both genes express a functional *C4* protein, and so does their fusion gene. Such monomodular haplotypes lacking one of the *C4* genes and the *CYP21A1P* gene occur at a frequency of 5%–20% in the general population.^{25,27-29}

An unequal crossover between *CYP21A1P* and *CYP21A2*, on the other hand, usually generates a fusion gene that is

Key points

- Defectiveness of the *CYP21A2* gene causes steroid 21-hydroxylase deficiency, a recessively inherited disorder of adrenocortical steroid biosynthesis.
- *CYP21A2* is part of a tandemly repeated structure known as the RCCX module, which may misalign during meiosis.
- A paternal de novo deletion of *CYP21A2* contributed to simple virilising steroid 21-hydroxylase deficiency in a patient who inherited the I172N mutation from his mother.
- The de novo deletion was caused by an unequal crossover occurring in a 640 bp region of the *TNXB* gene, adjacent to *CYP21A2*.
- By contrast with earlier observations, this unequal crossover occurred between chromosomes with equal numbers of RCCX modules.

CYP21A1P-like in its 5' section and contains several mutations rendering it inactive (a haplotype often referred to as a *CYP21A2* deletion). Absence of a functional *CYP21A2* gene is one of the defects that contributes to steroid 21-hydroxylase deficiency, the cause of over 90% of all cases of congenital adrenal hyperplasia. This is a disorder of adrenocortical steroid biosynthesis which in severe cases causes life threatening salt losing crises in untreated paediatric patients.¹⁸⁻²⁰

An unequal crossover between *TNXA* and *TNXB* not only eliminates the *CYP21A2* gene, but may also create a non-functional *TNXB/TNXA* hybrid that contains a 120 bp deletion on an exon-intron boundary normally present in *TNXA* only, and is therefore unable to express the tenascin-X protein. This defect contributes to the Ehlers-Danlos syndrome, a recessively inherited disease of connective tissue.^{17,30,31}

The mechanisms of these crossovers are difficult to understand, because usually only the recombinational end product is available for analysis. The concept of a deletion of the *CYP21A1P* pseudogene as a premutation has been proposed in a report on a de novo deletion of *CYP21A2* by recombination between a standard bimodular chromosome and a monomodular chromosome.³² More recently published studies also provide evidence that *TNXB/TNXA* hybrids are the result of a crossover between a bimodular and a monomodular chromosome.^{16,17}

Abbreviations: MHC, major histocompatibility complex; RCCX, RP-C4-CYP21-TNX module; PCR, polymerase chain reaction; TNF, tumour necrosis factor; *TNXB* (also known as *XA*), non-functional hybrid tenascin-X gene

Figure 1 Overview of a typical *C4/CYP21* area within the MHC class III region showing two RCCX modules as found on most chromosomes. *TNXB* is the full size 68 kb gene for tenascin-X. *TNXA* (also known as *XA*) is a truncated pseudogene of 5.7 kb that not only lacks most of the coding sequence of *TNXB* but also has a 120 bp deletion (indicated by the small triangle) spanning an exon-intron boundary.^{10 12 17} *CYP21A2* (also known as *CYP21B*) is the active steroid 21-hydroxylase gene; *CYP21A1P* (also known as *CYP21A*) is a full size pseudogene containing several deleterious mutations throughout its sequence, including three in phase stop codons.⁹ The *C4* genes express variants of the fourth component of complement with different affinities, known as *C4A* and *C4B*. About three quarters of the *C4* genes, including nearly all *C4A* genes, are "long" (20.6 kb in size); the others are "short" (14.2 kb). This difference is reflected in the size of the entire RCCX module, as the other components total approximately 12 kb. Assignment of *C4A* and *C4B* is tentative: the arrangement shown is the most common, but the specificity of the *C4* genes cannot be determined by means of the restriction sites shown. The arrows show the orientation of transcription; there is an overlap between the 3' sections of the oppositely transcribed genes *TNXB* and *CYP21A2*, and of *TNXA* and *CYP21A1P*, respectively. Several short transcripts encoded in the same region are not shown. Bottom: characteristic *TaqI*, *BglII*, and *SacII* restriction fragments. Only fragments mentioned in the text are shown; a *SacII* site internal to the RCCX module is not cut in genomic DNA, possibly owing to methylation. Top: scale in kb.

We report here a de novo unequal crossover that occurred between two bimodular chromosomes in the father of a patient with congenital adrenal hyperplasia caused by steroid 21-hydroxylase deficiency. The crossover site was mapped to a 640 bp region of the *TNXB* gene that starts at approximately 1.6 kb from the centromeric duplication boundary of the RCCX module. This de novo mutation eliminates the *CYP21A2* gene and also disrupts *TNXB* by replacing its 3' section by the corresponding part of *TNXA*, conveying the 120 bp deletion.

METHODS

Patient and family members

The patient, a boy, presented to the Sophia Children's Hospital at the age of 7 years 8 months with signs of precocious puberty. The patient was tall for his age (above the 90th centile), and bone age was very advanced (13.5 years). Basal plasma 17 α -hydroxyprogesterone was 99 nmol/l, testosterone was 4.3 nmol/l. Sodium and potassium concentrations were normal. The patient was diagnosed with simple virilising congenital adrenal hyperplasia caused by steroid 21-hydroxylase deficiency, and hydrocortisone replacement therapy, initially supplemented with cyproterone acetate, was installed. The family consists of both parents, the patient, two healthy brothers who are monozygotic twins, and a healthy sister. They were informed about the purpose of the study and gave their consent.

CYP21A2/C4 haplotyping

The family participated in our haplotyping study²⁸ as family 20, and *CYP21A2/C4* haplotypes³³ were established as described there. Briefly, genomic DNA was digested with *TaqI* or with *BglII*, separated by electrophoresis on agarose gels, Southern blotted onto nitrocellulose, and hybridised to the *CYP21A2* cDNA probe pC21/3c⁸ and the 5' section of the *C4* cDNA probe pAT-A.³ The resulting autoradiographic bands were quantified by laser densitometry with the exception of the 2.4 and 2.5 kb *TaqI* bands, which produced a weak hybridisation signal and were estimated visually. Long range restriction mapping by *SacII* digest and pulsed field gel electrophoresis was performed as described elsewhere.³⁴

CYP21A2 and *CYP21A1P* mutation analysis

Mutation analysis of all *CYP21A2* and *CYP21A1P* genes in this family was done as described before.³⁵ Briefly, three sections of

either *CYP21A2* or *CYP21A1P* were specifically amplified and hybridised to oligonucleotides detecting the most common mutations: intron2splice; exon3del8bp; I172N; I236N/V237E/M239K or I236K/V237E/M239K; V281L; exon7ins1bp; Q318X; R356W.

Analysis of flanking major histocompatibility complex (MHC) markers

Genomic DNA was digested with *EcoRI*, *HindIII*, *PvuII*, or *TaqI*, separated by electrophoresis and Southern blotted, and hybridised to the HLA-B probe pHLA2³⁶ and the HLA-DQ α probe pDCH-1,³⁷ resulting in distinctive banding patterns.³⁸ Length polymorphism of a microsatellite marker³⁹ near the tumour necrosis factor (TNF) locus was used as an additional marker.

Amplification and restriction analysis of *TNXA* and *TNXB*

Parts of *TNXA* and *TNXB* that encompass the site of the 120 bp deletion normally found in *TNXA* only were specifically amplified. The forward primer for *TNXB* (TCTCTGCCCTGGGAATGACAG) lies beyond the duplication boundary of the RCCX module, in the large non-duplicated part of the *TNXB* gene. The forward primer for *TNXA* (CTTGAGCTGCAGATGGGATAC) lies within the *RP2* pseudogene. The reverse primer (CAATCCCACCCTGAACAAGT) was the same for both genes, and lies between the site of the 120 bp deletion and the 3' end of the *CYP21A2/CYP21A1P* gene (fig 2). A touchdown polymerase chain reaction (PCR) protocol was used to amplify these stretches of approximately 2.7 kb: firstly, eight cycles of 30 seconds at 94°C, 60 seconds at 66°C decreasing 0.5°C per cycle, and three minutes at 72°C; next, 26 cycles of 30 seconds at 94°C, 60 seconds at 62°C, and three minutes at 72°C extending by 30 seconds per cycle. Amplification was done with 0.5 units of Thermopertect DNA polymerase (Integro, Leuvenheim, The Netherlands) in the presence of 1.5 mmol/l MgCl₂ and 1% formamide. The size of the PCR product directly shows the presence or absence of the 120 bp deletion/insertion.

Also, comparison of published *TNX* sequences (DDBJ/EMBL/GenBank accession numbers S38953,¹⁰ L26263,^{11 14} X71937,¹² AF077974,¹⁶ AF086641,¹⁷ AL049547,⁴⁰ AF019413,⁴¹ and U89337⁴²) showed several polymorphic sites throughout the amplified region, most of which can be detected by restriction analysis. Digestion of the PCR product with *Bst*UI

Figure 2 Amplified region of *TNXA* and *TNXB* showing the site of the 120 bp deletion in *TNXA*, the crossover, and the *ApaI* and *BstUI* restriction sites used to map it to a 640 bp region. The bold arrows represent the primer sites for the *TNX* PCRs; the reverse primer is the same for *TNXA* and *TNXB*, but the forward primers are specific and their starting positions differ by 34 bp, causing an additional size difference between the PCR products. The amplified stretches are: a (2654 bp): the father's first allele in the *TNXA* PCR (open box); b (2808 bp): the father's second allele in the *TNXB* PCR (densely hatched box); b/a (2688 bp): the hybrid found in the patient (densely hatched: from b; open: from a; lightly hatched: recombinant zone). The crossover region lies between the *BstUI* restriction site shown in allele a and the *ApaI* restriction site shown in allele a and in the b/a recombinant. Top: scale in bp, with underneath it the beginning of the 2.4 or 2.5 kb *TaqI* fragment that partly overlaps the *CYP21A2* or *CYP21A1P* gene (fig 1). Bottom: *ApaI* and *BstUI* restriction fragments, with * indicating polymorphic sites. The fragment sizes are the same as in fig 4. Variants indicate either the 34 bp difference in the location of the *TNXA* or *TNXB* forward primers (969/1003 and 670/704) or absence or presence of the 120 bp (350/470, 791/911, and 813/933).

(New England Biolabs, Beverly MA, USA) and *ApaI* (Eurogentec, Seraing, Belgium) proved particularly useful in locating the crossover site. *BstUI* detects a polymorphism at 1626 bp downstream of the duplication boundary of the RCCX module and *ApaI* detects a polymorphism at 2266 bp (in this context, downstream is relative to the transcription of the *TNXB* gene, and sequence AL049547 was used to compute fragment sizes and nucleotide positions).

RESULTS

CYP21/C4 haplotypes

The relative intensities of the *TaqI* and *BglII* restriction bands in this family are listed in table 1. The results, notably the diminished intensity of the *TaqI* 3.7 kb and the *BglII* 12 kb fragments in the patient, could not be explained by normal segregation of regular *CYP21/C4* haplotypes.²⁸ Long range restriction mapping by *SacII* digestion and pulsed field gel electrophoresis provides a size estimate of the entire contiguous array of RCCX modules, because the *SacII* sites lie just outside the duplicated region (fig 1).²⁶ In this family, both parents had 70 and 76 kb bands, typical of a bimodular arrangement with two long *C4* genes on one chromosome and one long and one short gene on the other chromosome. The patient, on the other hand, had one bimodular chromosome, but also showed a 43 kb band indicating the presence of a single RCCX module with a long *C4* gene on the other chromosome (fig 3). These results matched the *TaqI* and *BglII* band intensities (table 1). As testing of several independent genetic markers on chromosomes 1, 7, 16, and 21 confirmed paternity (results not shown), a de novo mutation seemed the most obvious explanation for these findings.

CYP21A2 mutation analysis

The I172N mutation was found in the mother, the patient, and the healthy daughter. This mutation is typical of the simple virilising form of congenital adrenal hyperplasia,⁴³ matching the patient's phenotype. None of the common deleterious mutations investigated³⁵ were found in the *CYP21A2* genes of

the patient's father or the twin brothers. Because the patient inherited a pre-existing genetic defect from his mother, the putative de novo deletion had apparently occurred in his father.

Confirmatory analysis of flanking MHC markers

The notion of a paternal de novo recombination was confirmed by analysis of markers centromeric (HLA-DQ α) and telomeric (TNF and HLA-B) to the RCCX module (details not shown). Normal Mendelian segregation of all alleles was shown in all healthy family members. The patient, however, carried the father's HLA-DQ α markers from one chromosome, together with the TNF and HLA-B markers from the other chromosome, as well as a normal maternal chromosome.

Combining these findings, it was concluded that an unequal crossover had occurred de novo between the father's chromosomes, eliminating the *CYP21A2* gene and the adjacent *C4* gene. The segregation of chromosome 6 in this family is shown in fig 3.

Analysis of the *CYP21A1P* pseudogene

Monomodular chromosomes lacking *CYP21A2* typically retain the *TaqI* 2.5 kb band matching *TNXB* (fig 1) because the single module is a hybrid with the recombination breakpoint located inside the *CYP21* gene.^{24 27 33} Surprisingly, in this patient the 2.4 kb band had a higher intensity than the 2.5 kb band (table 1), suggesting a crossover site in the *TNX* gene rather than in *CYP21*; both genes were further analysed to locate the breakpoint.

All *CYP21A1P* genes in this family matched the consensus sequence⁹ for all markers tested up to and including the fourth exon. Further downstream, distinctive markers (named after the matching codons in the *CYP21A2* gene) were found on each allele (fig 3). Presence of the L281 marker in the recombinant positioned the putative crossover site downstream of that marker, but the markers Q318 and R356 were not informative.

Figure 3 Pedigree of the family and long range restriction mapping. Characteristics of the haplotypes: a: *CYP21A2*(normal)-*C4*(long)-*CYP21A1P*-*C4*(long); b: *CYP21A2*(normal)-*C4*(short)-*CYP21A1P*-*C4*(long); c: *CYP21A2*(normal)-*C4*(long)-*CYP21A1P*-*C4*(long); d: *CYP21A2*(I172N)-*C4*(short)-*CYP21A1P*-*C4*(long); b/a: recombinant: *CYP21A1P*-*C4*(long). Distinctive markers in exons 7 and 8 of the *CYP21A1P* gene on each haplotype were: a: L281-G318-R356; b: V281-X318-R356; c: L281-X318-W356; d: V281-X318-R356; b/a: L281-G318-R356. All *CYP21A2* genes in this family carried the normal codons V281-G318-R356.³⁵ Bottom: *Sac*II digested genomic DNA separated by pulsed field gel electrophoresis and hybridised to a mix of a *CYP21A2* and a *C4* cDNA probe. F: father; M: mother; P: patient with a de novo deletion; C: control with two monomodular chromosomes (one with a long and one with a short *C4* gene). Right: fragment sizes in kb.

PCR and restriction analysis of the *TNX* genes

The PCR products of *TNXA* and *TNXB*, and restriction patterns after digestion with *Bst*UI and *Apa*I, are shown in figs 2 and 4. The 2688 bp band represents the recombinant *TNXB* gene of the patient, with the 120 bp deletion that has been transferred

from *TNXA* (fig 4A). The *TNXB* gene on the patient's other chromosome was apparently intact, as he did not have the Ehlers-Danlos syndrome.

The segregation of the fragments within the family allows assignment of the 120 bp deletion and the *Bst*UI and *Apa*I polymorphisms to each allele as listed in table 2. The recombinant matches the *TNXB* gene of chromosome b up to and including the *Bst*UI polymorphism 1626 bp downstream of the RCCX duplication boundary, and the *TNXA* gene of chromosome a from the *Apa*I polymorphism at 2266 bp. This implies that the crossover occurred in the 640 bp stretch that separates these sites, as shown in fig 2. A *Bse*RI polymorphism at 1951 bp and a *Pvu*II polymorphism at 2191 bp were not informative in this family (results not shown).

DISCUSSION

Deletions of approximately 30 kb of DNA containing the *CYP21A2* gene are a major factor in the genetics of steroid 21-hydroxylase deficiency. Such deletions have been attributed to unequal crossover owing to misalignment of homologous chromosomes during meiosis.^{16 17 27 32 44} In this report, we present such an unequal crossover as a de novo mutation in the father of a patient with steroid 21-hydroxylase deficiency. The crossover breakpoint was mapped to a 640 bp region between two polymorphic restriction sites in the *TNXB* gene, which lies immediately centromeric to the *CYP21A2* gene (figs 3 and 5). A de novo deletion of the *CYP21A2* gene reported earlier by Sinnott *et al*³² was caused by an unequal crossover between a chromosome with one RCCX module (monomodular: a single *C4* gene and a *CYP21A2* gene) and a chromosome with two RCCX modules (bimodular: two *C4* genes, a *CYP21A2* gene, and a *CYP21A1P* pseudogene). These authors point out that as the bimodular chromosome has no equally sized homologue to align to during meiosis, misalignment of its *CYP21A1P* and *TNXA* genes to the *CYP21A2* and *TNXB* genes of the monomodular chromosome would have a probability close to 50%. This notion of the common monomodular *CYP21A1P* deletion chromosome serving as a premutation was further strengthened by two more recent reports describing reciprocal *TNXB/TNXA* and *TNXA/TNXB* hybrids in unrelated persons.^{16 17} A de novo deletion that eliminated the *CYP21A1P* pseudogene⁴⁵ also involved one bimodular and one monomodular chromosome.

The current report shows that de novo unequal crossovers between bimodular chromosomes also contribute to the pathogenesis of steroid 21-hydroxylase deficiency. Fig 5 shows a misalignment that may explain such a rearrangement. It is reasonable to assume that the flanking sequences of the RCCX module, that is, the *TNXB* and *RPI* genes, will align correctly. The crossover could then be explained by two loops of DNA,

Table 1 Relative intensities of *Taq*I and *Bgl*II bands, and size of the *Sac*II bands, after hybridisation to *CYP21A2* and *C4* cDNA probes

	<i>CYP21A2</i> probe pC21/3c		<i>C4</i> probe pAT-A		<i>CYP21A2</i> and <i>C4</i> probes
	<i>Taq</i> I	<i>Bgl</i> II	<i>Taq</i> I	<i>Sac</i> II	Band sizes
	3.7 : 3.2*	2.5 : 2.4†	7.0 : 6.4 : 6.0 : 5.4‡		
Father	2 : 2	++ : ++	2 : 2	2 : 0 : 1 : 1	76 and 70 kb
Mother	2 : 2	++ : ++	2 : 2	2 : 0 : 1 : 1	76 and 70 kb
Patient	1 : 2	+ : ++	1 : 2	2 : 0 : 0 : 1	43 and 70 kb
Twin brothers	2 : 2	++ : ++	2 : 2	2 : 0 : 2 : 0	Not determined
Sister	2 : 2	++ : ++	2 : 2	2 : 0 : 1 : 1	Not determined

Ratios were measured by laser densitometry; ++, +: estimate, ++ indicating a higher intensity.

*3.7 kb: *CYP21A2* gene; 3.2 kb: *CYP21A1P* pseudogene (fig 1).

†2.5 kb: *TNXB* gene; 2.4 kb: *TNXA* pseudogene (fig 1).

‡7.0 kb: long *C4* gene in the most telomeric RCCX module; 5.4 kb: short *C4* gene in a non-telomeric RCCX module (fig 1); 6.4 kb and 6.0 kb (alternatives not shown in fig 1): short telomeric and long non-telomeric *C4* genes, respectively; the *C4* band sizes are those traditionally given in published reports,⁵ although the actual fragments are approximately 0.15 kb larger.

Figure 4 Full size and digested PCR products (fig 2); F, father; M, mother; P, patient; B, twin brother(s); S, sister; fragment sizes in bp. (A) *TNXB* PCR product showing the 120 bp size difference caused by the de novo unequal crossover; left: 5 µl SmartLadder (Eurogentec, Seraing, Belgium); electrophoresis was for 20 hours at 40 V on 1% agarose. (B) *TNXA* and *TNXB* *Bst*UI digest; left: 5 µl SmartLadder; electrophoresis was for 22 hours at 140 V on 3.2% polyacrylamide. (C) *Apal* digest; electrophoresis was for 10 hours at 50 V on 1.2% agarose. The twin brothers and the sister showed the same pattern as the mother in the *Bst*UI and *Apal* digests (results not shown). Fig 2 shows the size and position of the *Bst*UI and *Apal* fragments relative to the amplified region.

each comprising a single RCCX module. The size differences between the *C4* genes on the chromosomes involved may contribute to inducing such an arrangement. This difference is the result of the retroviral insert HERV-K(C4),^{46 47} and it has been hypothesised that such inserts may have contributed to genetic rearrangement in the MHC during evolution.⁴⁸

The presence of sequences promoting recombination, such as the *E coli* crossover hotspot instigator (χ), and the human minisatellite consensus sequence, has been implicated in genetic rearrangements of the RCCX module.^{17 43 49 50} It is possible that such sequences play a part in the generation of small scale gene conversions between the *CYP21A2* and *CYP21A1P* genes, but we do not think that at present there is any reason to assume that the RCCX module is a region of increased levels of crossover. Instead, the high degree of sequence homology between genes in this area combined with the frequent size differences and variability in the number of modules seems to promote misalignment, so that when a crossover does occur, it has an increased chance of producing a genetic rearrangement and potentially an inherited disease. Consistent with this notion, the present case is only the second clearly documented instance of a de novo unequal crossover causing a *CYP21A2* deletion, despite the fact that over the years, haplotyping studies that could have detected such events have been done in thousands of families by many different research groups around the world. The earlier

report³² was published before the structure of the RCCX module became known in detail,^{7 12–17} but the crossover apparently also occurred within the *TNXB* gene, because the 2.4 kb *Taq*I fragment was retained. Another case involved a very large area including HLA-D in the MHC class II region⁵¹ and probably arose by a mechanism different from the one discussed here.

Figure 5 Hypothetical misalignment and loop out of two bimodular chromosomes contributing to an unequal crossover causing deletion of a 30 kb region including the *CYP21A2* gene and the 3' portion of the *TNXB* gene. The figure shows separate loops of two sections of DNA, but other configurations involved in this crossover events can also be envisioned. The open and hatched boxes match the father's chromosomes a and b, and the sections of the patient's recombinant chromosome derived from them. Note that the scale in kb (top) and the restriction map (bottom) apply to the hybrid chromosome shown in the lower part of the figure, not to the looped out parental chromosomes in the upper part (see fig 1 for further details on the graphics).

Table 2 Presence and absence of polymorphic sites and the 120 bp insertion/deletion						
Chromosome	TNXA PCR			TNXB PCR		
	BstUI	Apal	120 bp	BstUI	Apal	120 bp
a	+	+	–	+	–	+
b	–	+	–	–	–	+
c	+	+	–	+	–	+
d	+	+	–	+	–	+
b/a recombinant	x	x	x	–	+	–

Presence (+) or absence (–) of the polymorphic *Bst*UI site at 1626 bp from the RCCX duplication boundary, of the *Apal* site at 2266 bp, and of the 120 bp (+, present; –, deleted) in the *TNXA* and *TNXB* genes on each chromosome (the letters match the alleles shown in fig 3; x: no PCR product: the recombinant cannot be amplified in the *TNXA* PCR)

Despite the small number of de novo deletions in this region described so far, it is remarkable that none of them seems to have its recombination breakpoint within the *CYP21A2* gene. It has been well documented that many apparent *CYP21A2* deletions represent a hybrid gene with a *CYP21A1P*-like 5' section and a *CYP21A2*-like 3' section, and that transition zones between these sections are positioned at different locations within the hybrid gene.^{27 35 49 52–55} In line with those findings, we did not find the 120 bp deletion in 15 other monomolecular deletion haplotypes after testing them with the *TNXB* specific PCR described here (unpublished data). *CYP21A2* gene deletions with the crossover site in the *TNXB* gene have so far been described in a few isolated cases, including this report.^{17 30–32} Whether the additional *TNXB* defect adds significantly to selection against this allele compared with a defect in *CYP21A2* alone is unclear, as the frequency of tenascin-X deficiency has not been established. However, steroid 21-hydroxylase deficiency alleles occur at different frequencies in different populations,^{29 35 53 55–63} and most reports do not describe putative crossover sites. This monomolecular dual deficiency haplotype may therefore play a part in the pathogenesis of congenital adrenal hyperplasia, the Ehlers-Danlos syndrome, or both, in some populations. Curiously, we recently found a relatively high frequency (four out of nine haplotypes) of *TNXB-TNXA* hybrids in bimolecular haplotypes with two *CYP21A1P*-like genes.⁶⁴ To establish the distribution of different classes of hybrid RCCX modules without a *CYP21A2* gene, studies in different populations could be done by means of PCR methods such as the one described here or elsewhere,^{17 30} or by checking the intensity ratio of the 2.4 and 2.5 kb *TaqI* bands on autoradiograms of genomic DNA. Analysis of de novo mutations in the male germline, which has previously been done for a small area within the *CYP21A2* gene,⁴⁴ can determine whether there are differences in the frequency of (unequal) crossover between different sections of the RCCX module.

Finally, the current report clearly illustrates that a de novo recombination may be a pitfall in understanding RCCX haplotypes, emphasising the importance of studying entire families rather than isolated patients. Usage of flanking markers on either side of the recombination site helps to avoid erroneous assignment of carrier status in such cases.

ACKNOWLEDGEMENTS

We thank Mr T Hoogenboezem for excellent technical assistance, Professor Dr S L S Drop for providing the family's blood samples, and Dr D J J Halley for her valuable comments about the manuscript.

Authors' affiliations

P F J Koppens, Department of Paediatrics, Erasmus MC Sophia, Rotterdam, The Netherlands

H J M Smeets, Clinical Genetics Centre Maastricht, Maastricht, The Netherlands

I J de Wijs, Department of Human Genetics, University Medical Centre Nijmegen, Nijmegen, The Netherlands

H J Degenhart, Department of Paediatrics, Erasmus MC Sophia, Rotterdam, The Netherlands

Correspondence to: Dr P F J Koppens, Erasmus MC, University Medical Centre, Rotterdam, Laboratory of Paediatrics, Room Ee1502b, PO Box 1738, 3000 DR Rotterdam, The Netherlands; p.koppens@erasmusmc.nl

REFERENCES

- 1 **MHC Sequencing Consortium**. Complete sequence and gene map of a human major histocompatibility complex. *Nature* 1999;**401**:921–3.
- 2 **International Human Genome Sequencing Consortium**. Initial sequencing and analysis of the human genome. *Nature* 2001;**409**:860–921.
- 3 **Belt KT**, Carroll MC, Porter RR. The structural basis of the multiple forms of human complement component C4. *Cell* 1984;**36**:907–14.
- 4 **Carroll MC**, Palsdottir A, Belt KT, Porter RR. Deletion of complement C4 and steroid 21-hydroxylase genes in the HLA class III region. *EMBO J* 1985;**4**:2547–52.

- 5 **Schneider PM**, Carroll MC, Alper CA, Rittner C, Whitehead AS, Yunis EJ, Collen HR. Polymorphism of the human complement C4 and steroid 21-hydroxylase genes. Restriction fragment length polymorphisms revealing structural deletions, homoduplications, and size variants. *J Clin Invest* 1986;**78**:650–7.
- 6 **Yu CY**. The complete exon-intron structure of a human complement component C4A gene. DNA sequences, polymorphism, and linkage to the 21-hydroxylase locus. *J Immunol* 1991;**146**:1057–66.
- 7 **Blanchong CA**, Chung EK, Rupert KL, Yang Y, Yang Z, Zhou B, Moulds JM, Yu CY. Genetic, structural and functional diversities of human complement components C4A and C4B and their mouse homologues, Slp and C4. *Int Immunopharmacol* 2001;**1**:365–92.
- 8 **White PC**, Grossberger D, Onufer BJ, Chaplin DD, New MI, Dupont B, Strominger JL. Two genes encoding steroid 21-hydroxylase are located near the genes encoding the fourth component of complement in man. *Proc Natl Acad Sci USA* 1985;**82**:1089–93.
- 9 **Higashi Y**, Yoshioka H, Yamane M, Gotoh O, Fujii-Kuriyama Y. Complete nucleotide sequence of two steroid 21-hydroxylase genes tandemly arranged in human chromosome: a pseudogene and a genuine gene. *Proc Natl Acad Sci USA* 1986;**83**:2841–5.
- 10 **Gitelman SE**, Bristow J, Miller WL. Mechanism and consequences of the duplication of the human C4/P450c21/gene X locus. *Mol Cell Biol* 1992;**12**:2124–34, erratum 3313.
- 11 **Matsumoto K**, Ishihara N, Ando A, Inoko H, Ikemura T. Extracellular matrix protein tenascin-like gene found in human MHC class III region. *Immunogenetics* 1992;**36**:400–3.
- 12 **Bristow J**, Tee MK, Gitelman SE, Mellon SH, Miller WL. Tenascin-X: a novel extracellular matrix protein encoded by the human XB gene overlapping P450c21B. *J Cell Biol* 1993;**122**:265–78.
- 13 **Sargent CA**, Anderson MJ, Hsieh SL, Kendall E, Gomez-Escobar N, Campbell RD. Characterisation of the novel gene G11 lying adjacent to the complement C4A gene in the human major histocompatibility complex. *Hum Mol Genet* 1994;**3**:481–8.
- 14 **Shen L**, Wu LC, Sanlioglu S, Chen R, Mendoza AR, Dangel AW, Carroll MC, Zipf WB, Yu CY. Structure and genetics of the partially duplicated gene RP located immediately upstream of the complement C4A and the C4B genes in the HLA class III region. *J Biol Chem* 1994;**269**:8466–76.
- 15 **Gomez-Escobar N**, Chou CF, Lin WW, Hsieh SL, Campbell RD. The G11 gene located in the major histocompatibility complex encodes a novel nuclear serine/threonine protein kinase. *J Biol Chem* 1998;**273**:30954–60.
- 16 **Rupert KL**, Rennebohm RM, Yu CY. An unequal crossover between the RCCX modules of the human MHC leading to the presence of a CYP21B gene and a tenascin *TNXB/TNXA*-RP2 recombinant between C4A and C4B genes in a patient with juvenile rheumatoid arthritis. *Exp Clin Immunogenet* 1999;**16**:81–97.
- 17 **Yang Z**, Mendoza AR, Welch TR, Zipf WB, Yu CY. Modular variations of the human major histocompatibility complex class III genes for serine/threonine kinase RP, complement component C4, steroid 21-hydroxylase CYP21, and tenascin *TNX* (the RCCX module). *J Biol Chem* 1999;**274**:12147–56.
- 18 **New MI**. Diagnosis and management of congenital adrenal hyperplasia. *Annu Rev Med* 1998;**49**:311–28.
- 19 **Wedell A**. Molecular genetics of congenital adrenal hyperplasia (21-hydroxylase deficiency): implications for diagnosis, prognosis and treatment. *Acta Paediatr* 1998;**87**:159–64.
- 20 **White PC**, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Endocr Rev* 2000;**21**:245–91.
- 21 **Milner CM**, Campbell RD. Genetic organization of the human MHC class III region. *Front Biosci* 2001;**6**:d914–26.
- 22 **Harada F**, Kimura A, Iwanaga T, Shimozawa K, Yata J, Sasazuki T. Gene conversion-like events cause steroid 21-hydroxylase deficiency in congenital adrenal hyperplasia. *Proc Natl Acad Sci USA* 1987;**84**:8091–4.
- 23 **Higashi Y**, Tanaka A, Inoue H, Fujii-Kuriyama Y. Evidence for frequent gene conversion in the steroid 21-hydroxylase P-450(C21) gene: implications for steroid 21-hydroxylase deficiency. *Am J Hum Genet* 1988;**42**:17–25.
- 24 **Morel Y**, André J, Uring-Lambert B, Hauptmann G, Bétuel H, Tossi M, Forest MG, David M, Bertrand J, Miller WL. Rearrangements and point mutations of P450c21 genes are distinguished by five restriction endonuclease haplotypes identified by a new probing strategy in 57 families with congenital adrenal hyperplasia. *J Clin Invest* 1989;**83**:527–36.
- 25 **Collier S**, Sinnott PJ, Dyer PA, Price DA, Harris R, Strachan T. Pulsed field gel electrophoresis identifies a high degree of variability in the number of tandem 21-hydroxylase and complement C4 gene repeats in 21-hydroxylase deficiency haplotypes. *EMBO J* 1989;**8**:1393–402.
- 26 **Dunham I**, Sargent CA, Dawkins RL, Campbell RD. Direct observation of the gene organization of the complement C4 and 21-hydroxylase loci by pulsed-field gel electrophoresis. *J Exp Med* 1989;**169**:1803–16.
- 27 **White PC**, Vitek A, Dupont B, New MI. Characterization of frequent deletions causing steroid 21-hydroxylase deficiency. *Proc Natl Acad Sci USA* 1988;**85**:4436–40.
- 28 **Koppens PFJ**, Hoogenboezem T, Halley DJJ, Barendse CAM, Oostenbrink AJ, Degenhart HJ. Family studies of the steroid 21-hydroxylase and complement C4 genes define 11 haplotypes in classical congenital adrenal hyperplasia in The Netherlands. *Eur J Pediatr* 1992;**151**:885–92.
- 29 **Ezquieta B**, Oliver A, Gracia R, Gancedo PG. Analysis of steroid 21-hydroxylase gene mutations in the Spanish population. *Hum Genet* 1995;**96**:198–204.

- 30 **Burch GH**, Gong Y, Liu W, Dettman RW, Curry CJ, Smith L, Miller WL, Bristow J. Tenascin-X deficiency is associated with Ehlers-Danlos syndrome. *Nat Genet* 1997;**17**:104–8.
- 31 **Schalkwijk J**, Zweers MC, Steijlen PM, Dean WB, Taylor G, van Vlijmen IM, van Haren B, Miller WL, Bristow J. A recessive form of the Ehlers-Danlos syndrome caused by tenascin-X deficiency. *N Engl J Med* 2001;**345**:1167–75.
- 32 **Sinnott PJ**, Collier S, Costigan C, Dyer PA, Harris R, Strachan T. Genesis by meiotic unequal crossover of a de novo deletion that contributes to steroid 21-hydroxylase deficiency. *Proc Natl Acad Sci USA* 1990;**87**:2107–11.
- 33 **Morel Y**, Miller WL. Clinical and molecular genetics of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. *Adv Hum Genet* 1991;**20**:1–68.
- 34 **Koppens PFJ**, Hoogenboezem T, Degenhart HJ. Duplication of the CYP21A2 gene complicates mutation analysis of steroid 21-hydroxylase deficiency: characteristics of three unusual haplotypes. *Hum Genet* 2002;**111**:405–10.
- 35 **Koppens PFJ**, Hoogenboezem T, Degenhart HJ. CYP21 and CYP21P variability in steroid 21-hydroxylase deficiency patients and in the general population in The Netherlands. *Eur J Hum Genet* 2000;**8**:827–36.
- 36 **Sood AK**, Pereira D, Weissman SM. Isolation and partial nucleotide sequence of a cDNA clone for human histocompatibility antigen HLA-B by use of an oligodeoxynucleotide primer. *Proc Natl Acad Sci USA* 1982;**79**:616–20.
- 37 **Auffray C**, Korman AJ, Roux-Dosseto M, Bono R, Strominger JL. cDNA clone for the heavy chain of the human B cell alloantigen DC1: strong sequence homology to the HLA-DR heavy chain. *Proc Natl Acad Sci USA* 1982;**79**:6337–41.
- 38 **Mornet E**, Boué J, Raux-Demay M, Couvilln P, Oury JF, Dumez Y, Dausset J, Cohen D, Boué A. First trimester prenatal diagnosis of 21-hydroxylase deficiency by linkage to HLA-DNA probes and by 17-hydroxyprogesterone determination. *Hum Genet* 1986;**73**:358–64.
- 39 **Nedospasov SA**, Udalova IA, Kuprash DV, Turetskaya RL. DNA sequence polymorphism at the human tumor necrosis factor (TNF) locus. Numerous TNF/lymphotoxin alleles tagged by two closely linked microsatellites in the upstream region of the lymphotoxin (TNFα) gene. *J Immunol* 1991;**147**:1053–9.
- 40 **Barlow K**. DDBJ/EMBL/GenBank accession number AL049547.
- 41 **Rowen L**, Dankers C, Baskin D, Faust J, Loretz C, Ahearn ME, Banta A, Schwartzell S, Smith TM, Spies T, Hood L. Sequence determination of 300 kilobases of the human class III MHC locus. DDBJ/EMBL/GenBank accession number AF019413.
- 42 **Rowen L**, Dankers C, Baskin D, Faust J, Loretz C, Ahearn ME, Banta A, Schwartzell S, Smith TM, Spies T, Hood L. Sequence determination of 300 kilobases of the human class III MHC locus. DDBJ/EMBL/GenBank accession number U89337.
- 43 **Amor M**, Parker KL, Globerman H, New MI, White PC. Mutation in the CYP21B gene (Ile-172>Asn) causes steroid 21-hydroxylase deficiency. *Proc Natl Acad Sci USA* 1988;**85**:1600–4.
- 44 **Tusié-Luna MT**, White PC. Gene conversions and unequal crossovers between CYP21 (steroid 21-hydroxylase gene) and CYP21P involve different mechanisms. *Proc Natl Acad Sci USA* 1995;**92**:10796–800.
- 45 **Fasano MB**, Winkelstein JA, LaRosa T, Bias WB, McLean RH. A unique recombination event resulting in a C4A*Q0,C4B*Q0 double null haplotype. *J Clin Invest* 1992;**90**:1180–4.
- 46 **Dangel AW**, Mendoza AR, Baker BJ, Daniel CM, Carroll MC, Wu LC, Yu CY. The dichotomous size variation of human complement C4 genes is mediated by a novel family of endogenous retroviruses, which also establishes species-specific genomic patterns among Old World primates. *Immunogenetics* 1994;**40**:425–36.
- 47 **Tassabehji M**, Strachan T, Anderson M, Campbell RD, Collier S, Lako M. Identification of a novel family of human endogenous retroviruses and characterization of one family member, HERV-K(C4), located in the complement C4 gene cluster. *Nucleic Acids Res* 1994;**22**:5211–7.
- 48 **Dawkins R**, Leelayuwat C, Gaudieri S, Hui J, Cattley S, Martinez P, Kulski J. Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. *Immunol Rev* 1999;**167**:275–304.
- 49 **Chu X**, Braun-Heimer L, Rittner C, Schneider PM. Identification of the recombination site within the steroid 21-hydroxylase gene (CYP21) of the HLA-B47,DR7 haplotype. *Exp Clin Immunogenet* 1992;**9**:80–5.
- 50 **Martínez-Quiles N**, Paz-Artal E, Moreno-Pelayo MA, Longás J, Ferre-López S, Rosal M, Arnaiz-Villena A. C4d DNA sequences of two infrequent human allotypes (C4A13 and C4B12) and the presence of signal sequences enhancing recombination. *J Immunol* 1998;**161**:3438–43.
- 51 **Heijmancik JF**, Black S, Harris S, Ward PA, Callaway C, Ledbetter D, Morris JM, Leech SH, Pollack MS. Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. *Hum Immunol* 1992;**35**:246–52.
- 52 **Donohoue PA**, Guethlein L, Collins MM, Van Dop C, Migeon CJ, Bias WB, Schmeckpeper BJ. The HLA-A3,Cw6,B47,DR7 extended haplotypes in salt losing 21-hydroxylase deficiency and in the Old Order Amish: identical class I antigens and class II alleles with at least two crossover sites in the class III region. *Tissue Antigens* 1995;**46**:163–72.
- 53 **Levo A**, Partanen J. Mutation-haplotype analysis of steroid 21-hydroxylase (CYP21) deficiency in Finland. Implications for the population history of defective alleles. *Hum Genet* 1997;**99**:488–97.
- 54 **l'Allemand D**, Tardy V, Grüters A, Schnabel D, Krude H, Morel Y. How a patient homozygous for a 30-kb deletion of the C4-CYP21 genomic region can have a non-classic form of 21-hydroxylase deficiency. *J Clin Endocrinol Metab* 2000;**85**:4562–7.
- 55 **Baumgartner-Parzer S**, Schulze E, Waldhäusl W, Pauschenwein S, Rondot S, Nowotny P, Meyer K, Frisch H, Waldhauser F, Vierhapper H. Mutational spectrum of the steroid 21-hydroxylase gene in Austria: identification of a novel missense mutation. *J Clin Endocrinol Metab* 2001;**86**:4771–5.
- 56 **Mornet E**, Crété P, Kuttann F, Raux-Demay MC, Boué J, White PC, Boué A. Distribution of deletions and seven point mutations on CYP21B genes in three clinical forms of steroid 21-hydroxylase deficiency. *Am J Hum Genet* 1991;**48**:79–88.
- 57 **Owerbach D**, Ballard AL, Draznin MB. Salt-wasting congenital adrenal hyperplasia: detection and characterization of mutations in the steroid 21-hydroxylase gene, CYP21, using the polymerase chain reaction. *J Clin Endocrinol Metab* 1992;**74**:553–8.
- 58 **Wedell A**, Thilén A, Ritzén EM, Stengler B, Luthman H. Mutational spectrum of the steroid 21-hydroxylase gene in Sweden: implications for genetic diagnosis and association with disease manifestation. *J Clin Endocrinol Metab* 1994;**78**:1145–52.
- 59 **Wilson RC**, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. *J Clin Endocrinol Metab* 1995;**80**:2322–9.
- 60 **Ordoñez-Sánchez M**, Ramírez-Jiménez S, López-Gutiérrez AU, Riba L, Gamboa-Cardiel S, Cerillo-Hinojosa M, Altamirano-Bustamante N, Calzada-León R, Robles-Valdés C, Mendoza-Morfin F, Tusié-Luna MT. Molecular genetic analysis of patients carrying steroid 21-hydroxylase deficiency in the Mexican population: identification of possible new mutations and high prevalence of apparent germ-line mutations. *Hum Genet* 1998;**102**:170–7.
- 61 **Lako M**, Ramsden S, Campbell RD, Strachan T. Mutation screening in British 21-hydroxylase deficiency families and development of novel microsatellite based approaches to prenatal diagnosis. *J Med Genet* 1999;**36**:119–24.
- 62 **Balsamo A**, Cacciari E, Baldazzi L, Tartaglia L, Cassio A, Mantovani V, Piazzini S, Cicognani A, Pirazzoli P, Mainetti B, Zappulla F. CYP21 analysis and phenotype/genotype relationship in the screened population of the Italian Emilia-Romagna region. *Clin Endocrinol* 2000;**53**:117–25.
- 63 **Krone N**, Braun A, Roscher AA, Knorr D, Schwarz HP. Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany. *J Clin Endocrinol Metab* 2000;**85**:1059–65.
- 64 **Koppens PFJ**, Hoogenboezem T, Degenhart HJ. Carriership of a defective tenascin-X (TNXB) gene in steroid 21-hydroxylase deficiency patients: consequences of breakpoint location in bimodular RCCX modules that lack the CYP21 gene. *Hum Mol Genet* 2002;**11**:2581–90.